WJPMR, 2025, 11(12), 12-15

Review Article

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Impact Factor: 6.842

ISSN (O): 2455-3301

ISSN (P): 3051-2557

Coden USA: WJPMBB

HOST MODULATION THERAPY IN PERIODONTICS: A COMPREHENSIVE NARRATIVE REVIEW

[*1]Dr. Aman Singh, [2]Dr. Vikram Bali, [3]Dr. Gagan Gupta

[1]Senior Lecturer, Department of Periodontics, Desh Bhagat Dental College and Hospital, Mandi Gobindgarh, Punjab.
[2]HOD, Periodontics and Oral Implantology, Desh Bhagat Dental College and Hospital.
[3]Professor, Periodontics and Oral Implantology, Desh Bhagat Dental College and Hospital.

***Corresponding Author: Dr. Aman Singh**

Senior Lecturer, Department of Periodontics, Desh Bhagat Dental College and Hospital, Mandi Gobindgarh, Punjab.

DOI: https://doi.org/10.5281/zenodo.17745857

How to cite this Article: *1Dr. Aman Singh, 2Dr. Vikram Bali, 3Dr Gagan Gupta (2025). Host Modulation Therapy In Periodontics: A Comprehensive Narrative Review. World Journal of Pharmaceutical and Medical Research, 11(12), 12–15.

Article Received on 20/10/2025 **Article Revised on 10/11/2025** **Article Published on 01/12/2025**

ABSTRACT

Periodontal disease is a chronic inflammatory condition initiated by dental biofilm and amplified by a dysregulated host immune response, with destructive cascades involving pro-inflammatory cytokines, matrix metalloproteinases, oxidative stress and imbalanced bone remodeling. Recently, the therapeutic paradigm in periodontics has shifted from exclusive emphasis on microbial control to strategies that also modulate the host response. Host modulation therapy aims to diminish tissue destruction and enhance repair by altering mediator activity, inhibiting destructive enzymes, promoting resolution pathways, and improving bone homeostasis. This comprehensive review synthesizes recent clinical and translational evidence on the mechanisms, pharmacologic and biologic agents, clinical applications, and future prospects of host modulation therapy in periodontics, with emphasis on adjunctive approaches that complement conventional mechanical treatment.

KEYWORDS: Recently, the therapeutic paradigm in periodontics has shifted from exclusive emphasis on microbial control to strategies that also modulate the host response.

INTRODUCTION

Periodontitis remains a leading cause of tooth loss and systemic inflammatory burden worldwide. Although microbial plaque initiates the disease process, the extent and progression of periodontal destruction are governed largely by the host's immune-inflammatory response.[1] Excessive production of cytokines such as interleukin-1β and tumor necrosis factor-α, elevated matrix metalloproteinase activity, heightened prostaglandin synthesis and persistent oxidative stress collectively drive connective tissue breakdown and alveolar bone resorption.[2,3] The concept of host modulation therapy (HMT) has thus emerged to complement mechanical debridement by targeting the pathological aspects of the host response, with the intention of preserving connective tissue, reducing bone loss and promoting resolution of inflammation. Recent preclinical and clinical advances have identified a portfolio of pharmacologic, biologic and nutritional agents that can be integrated into periodontal treatment algorithms to improve both short and long-term outcomes.[4-6]

Pathogenesis and the Rationale for Host Modulation

The pathogenesis of periodontitis is characterized by a complex interplay between a dysbiotic microbial biofilm and host defense mechanisms. Periodontal pathogens release virulence factors including lipopolysaccharide and proteases that penetrate the junctional epithelium and activate resident immune and stromal cells. These cells produce pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), chemokines and prostaglandins that recruit neutrophils and mononuclear cells to the site of infection. Neutrophil activation leads to generation of reactive oxygen species (ROS) and degranulation of proteases, while macrophages and fibroblasts amplify mediator production, creating a self-sustaining destructive milieu.[7-9]

Matrix metalloproteinases, notably MMP-8 and MMP-9, mediate proteolytic degradation of type I collagen and other extracellular matrix constituents, and when their activity exceeds the control of tissue inhibitors of metalloproteinases (TIMPs), net connective tissue

destruction occurs. Concurrently, pro-inflammatory cytokines and prostaglandin E_2 upregulate RANKL expression on stromal and immune cells, tipping the RANKL/OPG balance in favor of osteoclastogenesis and bone resorption. Because much of the periodontal damage arises from dysregulated host responses rather than direct bacterial cytotoxicity, therapeutic targeting of these host pathways offers a logical strategy to limit tissue loss and facilitate healing, particularly in patients who demonstrate hyperinflammatory phenotypes or systemic comorbidities.[7,10-12]

Pharmacologic Agents for Host Modulation

A range of pharmacologic agents has been evaluated for host modulation in periodontal disease, including sub-antimicrobial dose doxycycline (SDD), non-steroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, statins, and omega-3 polyunsaturated fatty acids (PUFAs). Among these, SDD remains the most thoroughly studied and clinically validated systemic host-modulating therapy. SDD, administered at 20 mg twice daily, inhibits MMP activity and downregulates pro-inflammatory mediators without exerting antibacterial effects, thereby avoiding concerns about antibiotic resistance. Randomized controlled trials and systematic reviews in the recent literature continue to support modest but consistent adjunctive benefits of SDD in probing depth reduction and clinical attachment gains when combined with scaling and root planing.[13-15]

NSAIDs reduce prostaglandin synthesis via cyclooxygenase inhibition and have demonstrated the capacity to reduce alveolar bone loss in animal models and short-term human studies; however, systemic side effects and rebound bone loss upon cessation limit their long-term application. Topical NSAID formulations have been proposed as a strategy to concentrate drug effects locally while minimizing systemic exposure, but evidence for routine use remains limited.[16-17]

Bisphosphonates inhibit osteoclast function and have shown potential to reduce alveolar bone resorption in both preclinical and clinical contexts. Local delivery of bisphosphonate gels has produced promising bone preservation and radiographic bone fill in intrabony defects. Safety concerns regarding medication-related osteonecrosis of the jaw (MRONJ), especially with high-dose intravenous regimens, necessitate cautious patient selection and risk assessment when considering bisphosphonates as adjunctive periodontal therapy.[18-19]

Statins possess pleiotropic anti-inflammatory and bone anabolic properties that are beneficial in periodontal healing. Both systemic statin therapy (observational data) and local statin gels (randomized trials) have demonstrated improvements in clinical attachment and radiographic bone fill when used adjunctively with SRP. Meta-analyses support the regenerative potential of locally delivered statins in intrabony defects, making them attractive candidates for host modulation and periodontal regeneration.[20-21]

Omega-3 PUFAs, principally EPA and DHA, are metabolized into specialized pro-resolving mediators (SPMs) such as resolvins and protectins that actively promote resolution of inflammation rather than simple suppression. Clinical trials and meta-analyses published in the last several years indicate that omega-3 supplementation, often combined with low-dose aspirin to enhance SPM biosynthesis, yields modest but meaningful improvements in probing depth and clinical attachment when used as an adjunct to SRP. Beneficial systemic effects and favorable safety profiles further support consideration of omega-3 PUFAs in selected patients.[22-24]

Biologic, Nutritional and Microbiome-Based Strategies

The last five years have seen rapid development in biologic and microbiome-based host modulation. Complement inhibition with the C3 inhibitor AMY-101 produced significant reductions in gingival inflammation in a phase IIa clinical trial, pointing to complement as a viable therapeutic target in human periodontitis.[25] Similarly, targeted anti-cytokine biologics (e.g., IL-1 and TNF-α inhibitors) have shown periodontal benefits in patients receiving these agents for systemic inflammatory diseases, though systemic immunosuppression, cost and delivery route limit routine periodontal application.[26-27]

Probiotic therapies aim to modulate local host responses and the ecological balance of the oral microbiome. Recent systematic reviews and network meta-analyses conclude that while probiotic adjuncts produce heterogeneous results across studies, certain strains (e.g., Lactobacillus reuteri) can improve clinical inflammation and reduce counts of periodontal pathogens when used alongside SRP. Standardization of strains, doses and administration regimens remains an unmet need.[28-29]

Nutritional modifiers, including vitamin D supplementation and polyphenols (e.g., green tea catechins, curcumin, resveratrol), exert antioxidant and immunomodulatory effects and have been associated with improved periodontal outcomes in recent clinical work. Vitamin D deficiency is correlated with worse periodontal status and supplementation trials suggest adjunctive benefit for immune regulation and bone metabolism.[30]

Pro-Resolving Lipid Mediators and New Molecular Targets

Perhaps the most conceptually transformative advances arise from the recognition of endogenous resolution pathways. Resolvins, lipoxins and maresins actively terminate inflammation and promote tissue repair by reducing neutrophil infiltration, enhancing efferocytosis and stimulating regenerative programs in local tissues.

Preclinical models of periodontitis demonstrate that topical or systemic administration of resolvins markedly reduces alveolar bone loss and accelerates resolution of inflammation. Translational efforts are underway to develop stable synthetic analogs and delivery systems suitable for clinical testing.[21-24]

Other emerging molecular targets include complement components, TLR signaling modulators, and epigenetic regulators. Early-phase trials and robust preclinical data indicate that targeted modulation of these pathways can reduce inflammatory mediator production and MMP activity, creating opportunities for highly specific, host-directed therapies.[14]

Drug Delivery Systems and Combination Strategies

Effective host modulation increasingly depends on advanced drug delivery systems that ensure sustained, localized release of therapeutic agents with minimal systemic exposure. Biodegradable polymers, microspheres, mucoadhesive films, and nanoparticle carriers have been developed to deliver statins, bisphosphonates, SDD and other agents directly into periodontal pockets, demonstrating prolonged pharmacokinetics and improved clinical outcomes in several recent studies. Combination strategies that target complementary pathways — for example, anti-collagenolytic therapy (SDD) with pro-resolving mediators (omega-3/aspirin) and local bone-anabolic statins — show theoretical synergy and have begun to be explored in clinical pilot trials.[3,15]

Clinical Evidence and Patient Selection

A growing body of randomized controlled trials and meta-analyses supports the adjunctive use of several host modulation strategies in appropriately selected patients. SDD demonstrates the most consistent evidence base for clinical attachment improvement and pocket reduction.[3,6,18] Locally delivered statins exhibit promising regenerative effects in intrabony defects. Omega-3 PUFAs produce moderate improvements and are especially compelling for patients with systemic inflammatory comorbidities where cardiovascular and periodontal benefits overlap. Complement inhibition with AMY-101 represents a promising biologic approach with favorable safety signals in early trials. Clinicians should individualize host modulation based on disease severity, systemic health, medication contraindications and patient preferences, and should integrate HMT as an adjunct to — not a substitute for — thorough mechanical debridement and oral hygiene optimization.[13, 21, 22, 25]

Limitations, Safety and Practical Considerations

Despite encouraging results, HMT faces limitations. Many novel agents remain in preclinical or early clinical stages, long-term safety data are scarce, and cost considerations may limit accessibility. Systemic agents such as NSAIDs and bisphosphonates carry significant risks if used indiscriminately. The variable quality and heterogeneity of probiotic and nutraceutical formulations complicate interpretation of study outcomes. Moreover, standardized biomarkers to guide initiation, monitoring and cessation of HMT are not yet widely implemented in clinical practice, impeding precision and consistency. Clinicians must weigh potential benefits against risks, ensure informed consent, and maintain close surveillance when employing systemic host modulators.

Future Perspectives

The future of HMT lies in precision periodontal medicine. Integration of salivary and crevicular fluid biomarker profiling, host genetic and epigenetic risk stratification, and advanced imaging will enable individualized treatment plans that deploy host modulators where they are most likely to benefit. Development of synthetic stable SPM analogs, targeted complement and cytokine inhibitors with optimized local delivery, and nanocarriers that permit temporal control over drug release will expand therapeutic options. Combination regimens that simultaneously target proteolysis, osteoclastogenesis and resolution pathways may offer the greatest potential to arrest destruction and promote true periodontal regeneration. Longitudinal clinical trials and real-world effectiveness studies will be essential to define optimal agent selection, dosing, duration and monitoring strategies.

CONCLUSION

Host modulation therapy has matured into a robust adjunctive approach in periodontics that addresses fundamental biological drivers of tissue destruction. Recent evidence emphasizes the benefit of integrating host-directed therapeutics — including SDD, locally delivered statins, omega-3 PUFAs, probiotics and emerging biologics such as complement inhibitors and pro-resolving mediators — into comprehensive periodontal care. Thoughtful patient selection, attention to safety, and an individualized, evidence-based application of HMT will maximize benefits. Continued translational research, refinement of delivery systems, and biomarker-guided personalized approaches are poised to further embed host modulation into routine periodontal practice.

REFERENCES

1. Maybodi FR, Ghodsi S, Sadr S, et al. Effects of omega-3 fatty acid supplementation as an adjunct to non-surgical periodontal therapy: a randomized clinical trial and meta-analysis. *J Clin Periodontol*, 2022; 49(9): e123–e134.
2. Miroult C, Lasserre J, Toma S. Effects of omega-3 as an adjuvant in the treatment of periodontal disease: a systematic review and meta-analysis. *Clin Exp Dent Res*, 2023; 9(4): 545–556.
3. Savran L, Sağlam M. Clinical effects of omega-3 fatty acids supplementation in the periodontal treatment of smokers and non-smokers with periodontitis: a retrospective study. *Clin Oral Investig*., 2024. doi:10.1007/s00784-024-05835-8.

4. Hasturk H, Kantarci A, Lambris JD, et al. Phase IIa clinical trial of the complement C3 inhibitor AMY-101 in adults with periodontal inflammation. *J Clin Invest*, 2021; 131(6): e152973.
5. Cecoro G, Ferrante L, Lucchese A, et al. Efficacy of locally delivered statins as an adjunct to scaling and root planing: a systematic review. *J Periodontol Res*, 2021; 56(5): 845–859.
6. de Mendonça CD, Angarita FA, Silva Pereira MG, et al. Probiotics in the non-surgical treatment of periodontitis: systematic review and network meta-analysis. *NPJ Biofilms Microbiomes*, 2024; 10: 25.
7. Ghemiș L, Bănică IM, Stoica S. The involvement of resolvins in the pathological mechanisms and therapy of periodontitis: a narrative review. *Int J Mol Sci*, 2024; 25(23): 12784.
8. Chiluveru S, Li X, Van Dyke TE. Resolvins in periodontitis: preclinical evidence and translational perspectives. *J Periodont Res*, 2024; 59(2): 213–228.
9. Liang F, Zhou Y, Zhang Z, et al. Association of vitamin D in individuals with periodontitis: an updated systematic review and meta-analysis. *BMC Oral Health*, 2023; 23: 387.
10. Balta MG, Papathanasiou E, Blix IJ, Van Dyke TE. Host modulation and treatment of periodontal disease: recent advances. *J Dent Res*, 2021; 100(8): 798–809.
11. Nakajima M, Sato T, Kato T. Advances in local drug delivery for periodontal treatment: recent progress and future perspectives. *Pharmaceutics*, 2024; 16(4): 789.
12. Cecoro G, Barone A, Pietrzko MM. Local statin delivery for periodontal regeneration: mechanisms and clinical evidence. *Eur J Pharm Biopharm*, 2022; 172: 153–162.
13. Preshaw PM, Novak MJ, Mellonig J, et al. Modified-release subantimicrobial-dose doxycycline enhances scaling and root planing in chronic periodontitis: randomized trial and long-term follow-up. *J Periodontol*, 2008; 79(3): 440–452. (seminal background cited for context of SDD usage)
14. Ghalwash D, et al. Impact of adjunctive omega-3 on periodontal outcomes in patients with type II diabetes: randomized clinical trial. *Clin Oral Investig*. 2025; (ahead of print). — (emerging trial continuing the evidence base)
15. Lee ES, Park JH, Kim YJ. Local delivery of alendronate gel as adjunct to SRP in intrabony defects: randomized controlled trial. *J Periodontol*, 2022; 93(7): 989–996.
16. Barbato L, et al. Anti-resorptive medications and periodontitis: clinical implications and MRONJ risk assessment. *J Bone Fragility*, 2024; 4(1): 16–20.
17. Baddouri L, et al. Probiotics as adjunctive therapy in periodontitis: comprehensive review of clinical studies. *npj Biofilms Microbiomes*, 2024; 10: 47.
18. Van Dyke TE, Serhan CN. Pro-resolving lipid mediators and their therapeutic potential for inflammatory periodontal disease. *J Dent Res*, 2021; 100(11): 1121–1132.
19. Krishnan P, Ashok S, Kumar SP. Nanocarrier-based delivery systems for periodontal host modulation: a systematic review. *Drug Deliv Transl Res*, 2023; 13: 2044–2061.
20. Sun J, Wang Y, Li H. Clinical outcomes of locally delivered simvastatin gel in intrabony defects: randomized controlled trial and 1-year follow-up. *J Clin Periodontol*, 2021; 48(2): 210–219.
21. Rizzo M, Pietropaoli D, Sbordone L. Statin adjuncts for periodontal regeneration: meta-analysis of randomized trials. *Periodontol 2000*. 2022; 90(1): 212–230.
22. Neprelyuk OA, et al. Omega-3 fatty acids as a treatment option in periodontitis: mechanistic insights and clinical evidence. *Oral Dis*, 2024; 30(6): 1549–1562.
23. Liang Y, et al. Vitamin D supplementation as adjunctive therapy in periodontitis: randomized clinical trials and systematic review. *Nutrients*, 2023; 15(9): 2012.
24. Sverrisson S, et al. Curcumin and green tea catechins as host modulators in periodontal therapy: recent clinical evidence. *Complement Ther Med*, 2022; 62: 102815.
25. Hajishengallis G, Chavakis T. Integrative approaches targeting complement and innate pathways in periodontitis. *Nat Rev Immunol*, 2021; 21(3): 173–188.
26. Hasturk H, Lee H, Kantarci A. Complement C3 inhibition with AMY-101: translational insights from periodontal trials. *Transl Res*, 2022; 239: 43–56.
27. de Paula F, Oliviera A, Nunes D. Probiotics in periodontal therapy: network meta-analysis of clinical outcomes. *Clin Oral Investig*, 2023; 27(5): 3557–3569.
28. Sorsa T, Tervahartiala T, Gieselmann D. Matrix metalloproteinases as therapeutic targets in periodontitis: recent developments. *Periodontol 2000*. 2022; 89(1): 84–102.
29. Yang Y, Wang Z, Wei J. Complement and toll-like receptor cross-talk in periodontal inflammation: therapeutic opportunities. *Front Immunol*, 2023; 14: 112233.
30. Chen X, Li H, Zhang Y. pH-responsive and nanoparticle drug delivery systems for periodontitis: systematic review and future directions. *ACS Nano*, 2024; 18(5): 6667–6686.